A successful Ph2 for myelofibrosis (SNT-5505) will see us taken out, most likely. This is the interim data being presented in December 2024 - 4 months away!
But if not a buyout, a licensing arrangement or partnership are most likely. A CR could be an option if we want to keep it all in-house and take the product to market ourselves, which is also a possibility, but a lot of money, time and effort to do so.
A successful Ph2 for myelofibrosis (SNT-5505) will see us taken...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.16M | |||
| Open | High | Low | Value | Volume |
| 3.6¢ | 3.6¢ | 3.3¢ | $56.97K | 1.623M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 859872 | 3.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.6¢ | 1069288 | 3 |
View Market Depth
| Last trade - 15.37pm 27/08/2024 (20 minute delay) ? |
| SNT (ASX) Chart |